[A17-60] Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Last updated 17.05.2018
Project no.:
A17-60
Commission:
Commission awarded on 23.11.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adults with moderate to severe plaque psoriasis
Indication of considerable added benefit in both subindications (systemic therapy suitable/not suitable)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-24 | Guselkumab (plaque psoriasis) - Addendum to Commission A17-60 | Commission completed |
| A20-112 | Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-05-17 A G-BA decision was published.